Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis.
Bhai S, Levine T, Moore D, Bowser R, Heim AJ, Walsh M, Shibani A, Simmons Z, Grogan J, Goyal NA, Govindarajan R, Hussain Y, Papsdorf T, Schwasinger-Schmidt T, Olney N, Goslin K, Pulley M, Kasarskis E, Weiss M, Katz SW, Moser S, Jabari D, Jawdat O, Statland J, Dimachkie MM, Barohn R; Neuromuscular Study Group and Western ALS Consortium Memantine ALS Study Group. Bhai S, et al. Among authors: grogan j. Muscle Nerve. 2025 Jan;71(1):63-72. doi: 10.1002/mus.28287. Epub 2024 Nov 7. Muscle Nerve. 2025. PMID: 39511965 Free PMC article. Clinical Trial.
Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis.
Quintana M, Saville BR, Vestrucci M, Detry MA, Chibnik L, Shefner J, Berry JD, Chase M, Andrews J, Sherman AV, Yu H, Drake K, Cudkowicz M, Paganoni S, Macklin EA; HEALEY ALS Platform Trial Study Group. Quintana M, et al. Ann Neurol. 2023 Sep;94(3):547-560. doi: 10.1002/ana.26714. Epub 2023 Jun 22. Ann Neurol. 2023. PMID: 37245090
Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development.
Paganoni S, Berry JD, Quintana M, Macklin E, Saville BR, Detry MA, Chase M, Sherman AV, Yu H, Drake K, Andrews J, Shefner J, Chibnik LB, Vestrucci M, Cudkowicz ME; Healey ALS Platform Trial Study Group. Paganoni S, et al. Ann Neurol. 2022 Feb;91(2):165-175. doi: 10.1002/ana.26285. Epub 2022 Jan 10. Ann Neurol. 2022. PMID: 34935174 Review.
Nutritional neuropathies.
Gwathmey KG, Grogan J. Gwathmey KG, et al. Among authors: grogan j. Muscle Nerve. 2020 Jul;62(1):13-29. doi: 10.1002/mus.26783. Epub 2019 Dec 26. Muscle Nerve. 2020. PMID: 31837157 Review.
Synergistic blockade of TIGIT and PD-L1 increases type-1 inflammation and improves parasite control during murine blood-stage Plasmodium yoelii non-lethal infection.
Dookie RS, Villegas-Mendez A, Cheeseman A, Jones AP, Barroso R, Barrett JR, Draper SJ, Janse CJ, Grogan JL, MacDonald AS, Couper KN. Dookie RS, et al. Among authors: grogan jl. Infect Immun. 2024 Nov 12;92(11):e0034524. doi: 10.1128/iai.00345-24. Epub 2024 Sep 26. Infect Immun. 2024. PMID: 39324794 Free article.
325 results